Observational study of ONIVYDE after gemcitabine for advanced pancreatic cancer
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This study watches how safe and effective a combination of chemotherapy drugs (ONIVYDE, 5-FU, and leucovorin) is for people with pancreatic cancer that has spread. It's for patients who have already tried gemcitabine without success, and the treatment is given as part of regular care, not as a separate experimental treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older and agree to take part in the study.
- Your doctor has already prescribed ONIVYDE (a chemotherapy drug) for you, as part of your normal care.
- You have a confirmed diagnosis of pancreatic cancer that started in the exocrine cells and has spread to other parts of the body.
- You have already tried gemcitabine (a standard chemotherapy) or a treatment that includes it, and it didn't work or you couldn't handle the side effects.
- You are not pregnant or breastfeeding, and you are willing to use effective birth control during treatment and for a few months after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well a chemotherapy combination (Onivyde plus 5-FU and leucovorin) works for people with advanced pancreatic cancer in China. It may help your doctor understand if this treatment is effective for you, especially if you have already tried a gemcitabine-based treatment.
This study compares two chemotherapy strategies for people with advanced pancreatic cancer who have not yet had treatment. The goal is to see if switching to a different chemotherapy combination (gemcitabine plus nab-paclitaxel) after initial treatment works better than staying on the original chemotherapy (modified FOLFIRINOX).
This trial tests a new immunotherapy drug (ivonescimab) combined with targeted radiation and chemotherapy for people with pancreatic cancer. The goal is to see if this combination can shrink tumors and improve outcomes.
This trial tests gemcitabine chemotherapy in people with metastatic pancreatic cancer who cannot take FOLFIRINOX. It aims to see how well gemcitabine works based on a specific tumor marker called GemCore.
This Phase 2 study compares two chemotherapy combinations to treat metastatic pancreatic cancer that has progressed after gemcitabine (with or without Abraxane). It aims to see which combination works better and is tolerable for people with measurable disease.
This Phase 1/2 study tests ONIVYDE® (a type of irinotecan drug) combined with carboplatin in people with advanced or metastatic gastroenteropancreatic poorly differentiated neuroendocrine carcinoma. The goal is to see how well the treatment works and how safely it can be given.
Hear when a new Metastatic Pancreatic Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.